tbuckley/cabot-search huggingface dataset:
AB1426-HPR Implementation of nurse led clinic in rheumatology department ljubljana, slovenia
Authors: D Stanković, M. Pavič Nikolič, A. Antonič Zakojč
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Nurse-led clinics in Rheumatology Department in Ljubljana have been established in September 2011 after nurses finished education module. The main goal was to provide good care and improved monitoring of patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis which are treated with biologics. In this way nurses started to contribute and shape new ways in helping patients to better manage their disease. With this new approach the nurses have applied some of the recommendations regarding the role of the nurse in treatment of patients with inflammatory rheumatic diseases. <h3>Objectives</h3> The aim of this study is to describe the organisation, purposes and activities of a nurse-led rheumatology clinics. <h3>Methods</h3> Nurse's intervention data was collected from January 2012 to December 2017. The data is allocated according to individual intervention which has been implemented. We used excel table to represent data. <h3>Results</h3> The patients have opportunity for telephone counselling with the dedicated nurse about issues with their anti-TNF therapies. Between January 2013 and May 2014 we collected data in which we recorded 101 calls from patients who were seeking information about biologics. We recorded how many patients had come to the nurse led-clinics. We sorted them in four groups; nurse led follow up clinics, education about self-administration of biologics or some other medicine, blood or skin tests and daily care unite (table 1). <h3>Conclusions</h3> The number of interventions has increased and show importance of nurses in patient management. This is most evident in the area of patient education and monitoring. <h3>Disclosure of Interest</h3> None declared
AB0565 Changes in health related quality of life in renaissance cohort of russian patients with systemic lupus erythematosus
Authors: E. Aseeva, L. Vorobyova, S. Soloviev, G. Koilubaeva, S. Glukhova
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The Lupus Quality of Life (LupusQol) is recommended to assess health related quality of life (HRQOL) in systemic lupus erythematosus (SLE). <h3>Objectives</h3> The aim of the current study was to assess HRQOL in the first year observation in cohort of patients with systemic lupus erythematosus in Russian Federation (RENAISSANCE). <h3>Methods</h3> The LupusQoL-Russian was administered to a cohort of 128 Russian patients affected with SLE at baseline and follow up visit (in 12 months). Disease activity was evaluated by the SLE disease activity Index-2000 (SLEDAI-2K), and chronic damage by the Systemic Lupus International Collaborating Clinics Damage Index score (SDI) at baseline and follow up visit. <h3>Results</h3> 128 patients (118 (92%) women; aged 33,02±11,04 years, mean disease duration 100,0±84,3 months) were included. At baseline mean SLEDAI 2K was 11,2±8,5; mean SDI – 1,3±1.6, mean daily prednisolone 16,8±10,9 mg/day). For 12 months all patients received standard therapy according SLEDAI 2K and their clinical manifestations (prednisolone 100%, Hydroxychloroquine 72,4%, Mycophenolate mofetil 25%, Cyclophosphamide 17%, Azathioprine 12,5%, Rituximab 27,3%, belimumab 12,5% pts). At follow up visit SLEDAI 2K score significantly improved up to 6,94±6,93 (p&lt;0,000029), SDI significantly worse up to 1,7±1,9 (p&lt;0,04), mean daily prednisolone significantly reduced up to 12,2±7,3 mg\day(p&lt;0,04). All 8 subscales LupusQol showed improvement in the 12 months versus baseline (table 1). Spearmen's correlation with SlEDAI 2K was obtained for Physical health (r=-0,13), Pain (r=-0,16), Planning (r=-0,21), Intimate relationship(r=-0,17) Burden to others(r=-0,16), emotional health (r=-0,13), Body image (r=-0,21). <h3>Conclusions</h3> The LupusQoL-Russian is sensitive to change in SLE patients with active SLE. The HRQOL correlated with disease activity, daily prednisolone and biologic. <h3>Disclosure of Interest</h3> None declared
Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes
Authors: Monzr Al Malki, Sanjeet Dadwal, Dongyun Yang, Sally Mokhtari, Thai Cao, Ketevan Gendzekhadze, David S Snyder, Haris Ali, Ibrahim Aldoss, Amandeep Salhotra, Guido Marcucci, Chatchada Karanes, Pablo Parker, Auayporn P. Nademanee, Don Diamond, John Zaia, Stephen J Forman, Ryotaro Nakamura
Journal: Blood (2018)
THU0428 Skin score changes in early diffuse cutaneous systemic sclerosis (DCSSC) patients are associated with overall disease severity
Authors: T. Nevskaya, M. Baron, B. Zheng, C.A. Baxter, D.R. Ramey, J.E. Pope
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To determine if skin changes over 2 years are associated with changes in organ involvement in early diffuse cutaneous systemic sclerosis (dcSSc). <h3>Methods</h3> dcSSc with ≤5 years disease duration followed for 2 years from the Canadian Scleroderma Research Group (CSRG) registry were studied for organ involvement using the Medsger Disease Severity Score (DSS) with ≥1 point changes (decrease or increase) considered improvement or progression, correspondingly. Other disease measures were assessed including pulmonary function, patient and physician globals, functional disability and quality of life. Modified Rodnan Skin Score (mRSS) improvement was defined as a decrease of ≥5 points and/or a≥25% reduction. Adjusted regression analysis, ANOVA, chi-square, t-test and Pearson’s tests were used. <h3>Results</h3> Of the 128 patients, mRSS improved for 50% from 22.6 to 18.1 (p=0.0001). More skin-improvers improved in severity of lung (39% vs 17%, p=0.006), joint/tendon (50% vs 21%, p=0.017), and any visceral organ involvement (renal, cardiac, pulmonary or gastrointestinal) (60% vs 27%, p=0.031) compared to mRSS non-improvers. Skin-improvers less often developed new skin ulcers (0% vs 11%, p=0.015) and GI disease (5% vs 18%, p=0.023), as well as progression of joint/tendon involvement (7% vs 29%, p=0.02). Improving mRSS correlated with changes in total Medsger’s severity score (without skin domain), severity of lung, GI, and peripheral vascular disease (table 1). FVC% stabilised in skin-improvers vs. worsened by 6.5% in non-improvers, p=0.026. Physician global assessments (severity, activity, damage) HAQ-DI, and SF-36 PCS improved more with improved mRSS (p&lt;0.003, p=0.001, p=0.005 respectively). Improvement in Forced Vital Capacity% predicted correlated with skin improvement (r=0.33, p=0.004). <h3>Conclusions</h3> Over two years, improving skin scores in dcSSc were associated with an improvement in lung disease, joint/tendon, physician global assessments, HAQ-DI, SF-36 PCS, and overall visceral organ improvement. Improvement in mRSS as a primary outcome in drug trials is likely to be concordant with improvement in organ involvement and several other disease measurement domains in early dcSSc. <h3>Disclosure of Interest</h3> T. Nevskaya Grant/research support from: Merck and Co., Inc., Kenilworth NJ, USA, M. Baron Grant/research support from: Merck and Co., Inc., Kenilworth NJ, USA, B. Zheng Grant/research support from: Merck and Co., Inc., Kenilworth NJ, USA, C. Baxter Employee of: MSD Ltd, Hoddesdon, UK, D. Ramey Employee of: Merck and Co., Inc., Kenilworth NJ, USA, J. Pope Grant/research support from: Merck and Co., Inc., Kenilworth NJ, USA
Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies
Authors: Saikat Ghosh, Rohan Lalani, Vivek Patel, Denish Bardoliwala, Kuntal Maiti, Shubhadeep Banerjee, Subhas Bhowmick, Ambikanandan Misra
Journal: Journal of Controlled Release (2019)
THU0273 Prevalence of vertebral fractures in ankylosing spondylitis: a meta-analysis
Authors: J. Sahuguet, J. Mancini, P. Lafforgue, T. Pham
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Osteoporosis is a well-recognised feature of ankylosing spondylitis (AS). Patients with AS have an increased risk of vertebral fractures (VF) but prevalence of VF is variable across studies from 4% to 42%. The diagnosis of VF is still problematic because frequently asymptomatic and sometimes difficult to differentiate from vertebral deformities which are not fractures. <h3>Objectives</h3> The aim of our study was to determine the prevalence of VF in AS and the risk factors associated. <h3>Methods</h3> Two independent investigators conducted a search in Medline and Cochrane databases, including cohorts, cross-sectional, and case-control studies that had assessed the prevalence of VF in patients with AS fulfilling the modified New York criteria. We collected data about study design, demographics, disease activity and severity (HLA B27 antigen status, BASDAI, BASFI, ASDAS, mSASSS, CRP, ESR, treatment history), bone mineral density, method of VF assessment (method of X-rays reading, number of readers) and characteristics of VF (number, prevalence, grade). <h3>Results</h3> Among 434 screened studies, 17 were eligible for meta-analysis. The pooled VF prevalence in patients with AS was 19% (95% CI 14%&gt;24%, I<sup>2</sup>90.5%) (figure 1). The CRP (p&lt;0.001) and mSASSS (p=0.046) scores were associated with a higher risk of VF. When focusing only on moderate to severe VF, HLA B27 antigen (p=0.046), lumbar spine osteoporosis (p=0.018) and osteopenia (p=0.024), hip BMD (p=0.024), CRP (p=0.004), ESR (p&lt;0.001), and Genant method (p=0.009) were associated with higher risk of VF. <h3>Conclusions</h3> Despite a large heterogeneity among studies, the prevalence of VF in AS patients is high. CRP and mSASSS scores were associated with the prevalence of all VF. Classical VF risk factors, such as osteoporosis, were associated only with moderate and severe VF. <h3>Disclosure of Interest</h3> None declared
Cancer statistics, 2019
Authors: Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2019)

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2016, were collected by the National Center for Health Statistics. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2006-2015) was stable in women and declined by approximately 2% per year in men, whereas the cancer death rate (2007-2016) declined annually by 1.4% and 1.8%, respectively. The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the racial gap in cancer mortality is slowly narrowing, socioeconomic inequalities are widening, with the most notable gaps for the most preventable cancers. For example, compared with the most affluent counties, mortality rates in the poorest counties were 2-fold higher for cervical cancer and 40% higher for male lung and liver cancers during 2012-2016. Some states are home to both the wealthiest and the poorest counties, suggesting the opportunity for more equitable dissemination of effective cancer prevention, early detection, and treatment strategies. A broader application of existing cancer control knowledge with an emphasis on disadvantaged groups would undoubtedly accelerate progress against cancer.
Fiber Reinforced Cartilage ECM Functionalized Bioinks for Functional Cartilage Tissue Engineering
Authors: Swetha Rathan, Léa Dejob, Rossana Schipani, Benjamin Haffner, Matthias E. Möbius, Daniel J. Kelly
Journal: Advanced Healthcare Materials (2019)

Focal articular cartilage (AC) defects, if left untreated, can lead to debilitating diseases such as osteoarthritis. While several tissue engineering strategies have been developed to promote cartilage regeneration, it is still challenging to generate functional AC capable of sustaining high load-bearing environments. Here, a new class of cartilage extracellular matrix (cECM)-functionalized alginate bioink is developed for the bioprinting of cartilaginous tissues. The bioinks are 3D-printable, support mesenchymal stem cell (MSC) viability postprinting and robust chondrogenesis in vitro, with the highest levels of COLLII and ACAN expression observed in bioinks containing the highest concentration of cECM. Enhanced chondrogenesis in cECM-functionalized bioinks is also associated with progression along an endochondral-like pathway, as evident by increases in RUNX2 expression and calcium deposition in vitro. The bioinks loaded with MSCs and TGF-β3 are also found capable of supporting robust chondrogenesis, opening the possibility of using such bioinks for direct "print-and-implant" cartilage repair strategies. Finally, it is demonstrated that networks of 3D-printed polycaprolactone fibers with compressive modulus comparable to native AC can be used to mechanically reinforce these bioinks, with no loss in cell viability. It is envisioned that combinations of such biomaterials can be used in multiple-tool biofabrication strategies for the bioprinting of biomimetic cartilaginous implants.
THU0403 Serum levels of macrophage migration inhibitory factor and interleukin-1 family cytokines are elevated in systemic sclerosis
Authors: E. Lin, F. Vincent, J. Harris, R. Kandane-Rathnayake, G.-S. Ngian, J. Sahhar, E. Morand, T. Lang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic sclerosis (SSc) is an autoimmune connective tissue disorder, the pathogenesis of which remains unknown. Recent evidence suggests dysregulation of the innate immune system, particularly interleukin-(IL)−1 family cytokines. Given the emerging role of macrophage migration inhibitory factor (MIF) in pathways of IL-1 family cytokine secretion, the role of MIF, IL-1α, IL-1β and IL-18 in SSc is of interest. <h3>Objectives</h3> To examine associations between MIF and IL-1 cytokines (IL-1α, IL-1β, IL-18), in SSc, and associations with clinical features. <h3>Methods</h3> 115 SSc patients (2013 ACR/EULAR criteria) attending Monash Scleroderma Clinic and 52 healthy controls were recruited between August 2015 and August 2017. Serum MIF, IL-1α, IL-1β and IL-18 levels were quantified using ELISA and analysed alongside concurrent clinical and laboratory data from the Australian Scleroderma Cohort Study database <h3>Results</h3> Compared to controls, SSc patients had significantly elevated serum MIF and IL-18 (figure 1). A weak positive correlation was observed between MIF and SScHAQ score (R=0.2107, p=0.0437) which was stronger in the diffuse cutaneous (dcSSc) subgroup (R=0.457, p=0.0373). Patients with elevated IL-18 levels were more likely to have active disease (EUSTAR score ≥3) however IL-18 was lower in patients with pulp atrophy and sclerodactyly. IL-1β was elevated in dcSSc patients with pulmonary fibrosis and correlated with mRSS (R=0.213, p=0.0254) in all SSc patients. IL-1α was elevated in patients with joint contractures and pulp atrophy. Positive correlations were found between concentrations of MIF and both IL-1α and IL-1β. However, there was no significant correlation between MIF and IL-18. <h3>Conclusions</h3> MIF and IL-18 were significantly elevated in SSc compared to health controls, and IL-1 family cytokines were variably associated with clinical manifestations of SSc. A relationship between MIF and IL-1β was confirmed. Further investigation into the roles of MIF and IL-1 family cytokines in SSc is justified. <h3>References</h3> [1] Zhang L, Yan JW, Wang YJ, Wan YN, Wang BX, Tao JH, et al. Association of interleukin 1 family with systemic sclerosis. Inflammation2014;37(4):1213–20. [2] van Bon L, Cossu M, Radstake TR. An update on an immune system that goes awry in systemic sclerosis. Curr Opin Rheumatol2011;23(6):505–10. <h3>Disclosure of Interest</h3> None declared
SAT0303 Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: results of a danish prospective, exploratory cohort study
Authors: P. Højgaard, K. Ellegaard, S.M. Nielsen, R. Christensen, J. Guldberg-Møller, C. Ballegaard, L. Dreyer, P. Mease, M. de Wit, L. Skov, B. Glintborg, H. Bliddal, E.M. Bartels, K. Amris, L.E. Kristensen
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Pain is a major concern for patients with psoriatic arthritis (PsA) in spite of treatment with biologic/conventional disease modifying drugs (b/csDMARDS). Studies on the prognostic role of pain mechanisms in PsA, are scarce. <h3>Objectives</h3> To investigate the presence of widespread non-arthritic pain (WP) in patients with PsA, and determine its relation to patient-reported, clinical- and ultrasound (US) disease measures, as well as to achievement of 4 months response to b/csDMARD therapy. Secondly, to study if US Colour Doppler activity (CD) at baseline is associated to treatment response. <h3>Methods</h3> A prospective cohort study was performed following a protocol.<sup>1</sup>Patients initiating b/csDMARDs for PsA were recruited from rheumatology clinics in Copenhagen. Clinical- and US examinations and patient-reported outcomes (PROs) were performed at baseline and after 4 months. WP was defined as a Widespread Pain Index≥4, and pain in ≥4/5 regions. CD activity in selected joints, entheses and tendons (73 projections) was summed. Response was assessed by American College of Rheumatology 20% (ACR20), Disease Activity in Psoriatic Arthritis 50% (DAPSA 50) and Minimal Disease Activity (MDA). Main response analyses were based on intention to treat with non-responder imputation, and consisted of logistic regressions adjusting for gender and age. <h3>Results</h3> Of 123 screened patients, 69 were included. Of these, 24 (35%) fulfilled the WP definition. At baseline (Table), WP was associated with worse PROs and composite scores, while CD activity and clinical measures were similar to those without WP. WP profile was significantly related to achievement of MDA at follow-up but not to other response criteria (table 1). Presence of CD activity at baseline was not significantly associated to 4 months response by any criteria, e.g. 19%/31% with CD=0/CD &gt;0, reached ACR20, (p=0.262). <h3>Conclusions</h3> WP was present in 1/3 of patients, and associated with worse PROs, composite measures, and failure to achieve MDA at follow-up. Neither WP nor CD at baseline was related to other response measures. <h3>Reference</h3> Højgaardet al. BMJ Open2006;6. doi:10.1136/bmjopen-2015-010650 <h3>Acknowledgements</h3> Thanks to: The Oak foundation, Danish Rheumatism Association, Centre for Rheumatology Gentofte Hospital. <h3>Disclosure of Interest</h3> None declared
FRI0309 The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus
Authors: I. Parodis, A.H. Lopez Benavides, A. Zickert, S. Pettersson, S. Möller, E. Welin Henriksson, A. Voss, I. Gunnarsson
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Accumulating evidence supports an impaired health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE). The impact of modern therapeutic interventions on patients' perception of HRQoL has not been explored in depth. <h3>Objectives</h3> The aim of this study was to investigate the effects of two biologic treatments – belimumab and rituximab – on SLE patients' HRQoL, fatigue and functional ability. <h3>Methods</h3> Patients with SLE from the Karolinska University Hospital treated with either belimumab (n=34) or rituximab (n=35) were included. Data were collected prospectively at treatment initiation and at months 3, 6, 12 and 24; these included the Medical Outcome Study short form-36 (SF-36) version 2, functional assessment of chronic illness therapy (FACIT)-Fatigue scale version 4, EuroQol research foundation 5-dimension (EQ-5D) health questionnaire, and Stanford health assessment questionnaire disability index (HAQ-DI). <h3>Results</h3> Substantial reductions compared to Swedish norms were observed across all SF-36 subscales at baseline (figure 1). SF-36 mental component summary scores were higher in patients who were on antimalarial agents (mean: 42.7; SD ±11.8; n=29) compared to patients who were not (mean: 34.0; SD ±14.7; n=32; p=0.019). Accordingly, patients who were on antimalarial agents performed better in SF-36 social functioning (mean: 63.7 versus 46.5; p=0.022) and mental health (mean: 68.7 versus 53.4; p=0.023) compared to patients who were not. Belimumab-treated patients reported gradual improvements in the SF-36 physical summary component (significant from month 12; p=0.023) and FACIT-Fatigue (significant by month 24; p=0.001), no changes in EQ-5D scores, and improvements in HAQ-DI by month 6 (p=0.014). Rituximab-treated patients reported rapid improvements in the SF-36 mental summary component and FACIT-Fatigue by month 3 (p=0.031 and p=0.007, respectively), which declined at month 12, as well as improvements in EQ-5D at month 6 (p=0.016) and HAQ-DI at month 3 (p=0.033), which were not maintained at later time points. <h3>Conclusions</h3> HRQoL was considerably impaired in SLE patients compared to population-based norms at baseline, and was not fully compensated during follow-up. Patients' perceptions of HRQoL showed treatment-specific patterns over time, and could prove useful when evaluating the effects of biologics in SLE. Early evaluation of belimumab might underestimate improvements in HRQoL and fatigue. In severe SLE, antimalarial agents may have favourable effects on mental HRQoL aspects. <h3>Disclosure of Interest</h3> None declared
Abstract 19410: Impact of Increasing Body Mass Index on Physician Radiation Exposure During Cardiac Catheterization
Authors: Austin Clarey, Edwin Mandieka, Jake Bundy, David Benavides, Thomas Crane, Emily Pardington, Sheetal Maragiri, Erica Osip, Taylor Ten Brock, Matthew Elmore, Abbey Mulder, Stacie VanOosterhout, Jessica Parker, Ryan Madder
Journal: Circulation (2017)

Introduction: Considering that obese patients emit greater amounts of scatter radiation during fluoroscopic procedures, it is possible that the growing obesity epidemic could adversely affect the occupational health of physicians performing cardiac catheterization. This study was performed to determine the impact of BMI on physician radiation exposure during cardiac catheterization. Methods: Real-time radiation exposure data were prospectively collected from dosimeters worn by physicians performing cardiac catheterization. Using data from an outer dosimeter (Hos) and body dosimeter (Hu), the physician effective dose per case (E) was calculated as E = 0.02 (Hos - Hu) + Hos. Patient radiation dose for each case was estimated using the dose-area product (DAP) automatically generated by the fluoroscopy system. Patient BMI was categorized using the NIH classification. DAP and effective dose are reported as median [25th, 75th percentile]. Results: Among 1,068 consecutive cardiac catheterizations, patient BMI wa...